Brian Kaspar
About Brian Kaspar
Brian Kaspar serves as the Chief Scientific Officer at Insmed Incorporated, where he focuses on developing gene therapies and protein therapeutics for rare diseases. With over 20 years of experience in gene therapy, he has contributed to significant advancements in the field and co-founded multiple biotechnology companies.
Work at Insmed
Brian Kaspar has served as the Chief Scientific Officer at Insmed Incorporated since August 2021. His role involves leading the company's efforts in developing novel gene therapies and protein therapeutics aimed at addressing rare diseases. He joined Insmed following the company's acquisition of a gene therapy company he co-founded. His work at Insmed includes collaboration with research teams located in San Diego, New Hampshire, New Jersey, and Cambridge, UK, focusing on advancing gene therapy and protein manufacturing technologies.
Education and Expertise
Brian Kaspar holds a Ph.D. in Molecular Pathology from UC San Diego and a Bachelor of Science in Neurobiology and Neurosciences from the University of Illinois Urbana-Champaign. He has over 20 years of experience in gene therapy development and manufacturing, with specific expertise in neuroscience and adeno-associated virus gene therapy. His scientific training includes experience at the University of San Diego and the Salk Institute for Biological Studies.
Background
Before joining Insmed, Brian Kaspar held various positions in academia and industry. He worked as a Research Fellow at the Salk Institute for Biological Studies from 1999 to 2004 and served as a Professor of Pediatrics at The Research Institute at Nationwide Children's Hospital from 2004 to 2017. He was also a Scientific Founder at Milo Biotechnology from 2010 to 2023. His academic roles included faculty positions at The Ohio State University and Nationwide Children's Hospital.
Achievements
Brian Kaspar has contributed significantly to the field of gene therapy, including the development and commercialization of a gene therapy for Spinal Muscular Atrophy. He is a co-inventor on numerous patent applications and has co-authored over 100 scientific publications in high-impact journals. His involvement in biotechnology includes the creation of companies such as AveXis, where he served as Chief Scientific Officer.